ENDRA Life Sciences Files 8-K on Financials

TL;DR

ENDRA Life Sciences dropped an 8-K on 8/22 detailing financials - check it out.

AI Summary

ENDRA Life Sciences Inc. filed an 8-K on August 23, 2024, reporting on its results of operations and financial condition as of August 22, 2024. The filing includes financial statements and exhibits, indicating a regulatory disclosure event. The company, previously known as Endra Inc., is incorporated in Delaware and headquartered in Ann Arbor, Michigan.

Why It Matters

This 8-K filing provides an update on ENDRA Life Sciences' financial condition and operations, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant negative news or events.

Key Players & Entities

• ENDRA Life Sciences Inc. (company) — Registrant
• Endra Inc. (company) — Former company name
• August 22, 2024 (date) — Date of earliest event reported
• August 23, 2024 (date) — Filing date
• Ann Arbor, MI (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share NDRA The Nasdaq Stock Mar

Filing Documents

• endra_8k.htm (8-K) — 25KB
• endra_ex991.htm (EX-99.1) — 114KB
• endra_ex992.htm (EX-99.2) — 35KB
• 0001654954-24-011072.txt ( ) — 314KB
• endra-20240822.xsd (EX-101.SCH) — 6KB
• endra-20240822_lab.xml (EX-101.LAB) — 14KB
• endra-20240822_cal.xml (EX-101.CAL) — 1KB
• endra-20240822_pre.xml (EX-101.PRE) — 9KB
• endra-20240822_def.xml (EX-101.DEF) — 2KB
• endra_8k_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On August 22, 2024, ENDRA Life Sciences Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On August 22, 2024, the Company held a conference call to discuss its financial results for the three months ending June 30, 2024. The Company has prepared a transcript of that conference call, a copy of which is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information furnished under Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 22, 2024, furnished herewith. 99.2 Transcript of conference call held on August 22, 2024 at 4:30 pm, furnished herewith. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENDRA Life Sciences Inc. August 23, 2024 By: /s/ Richard Jacroux Name: Richard Jacroux Title: Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR